Physician profile
Hannah Harrison
NPI 1871973768
$3,722.39
in general payments reported to CMS, 2019-2025
25 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.59 · 2022: $60.13 · 2023: $99.24 · 2024: $1,846 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,630 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.01 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $854.17 | 2024-2025 | |
| Glaxosmithkline, LLC. | $529.20 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $379.06 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $288.10 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Genentech USA, INC. | $166.67 | 2024-2025 | Xolair |
| Optinose US, INC. | $165.29 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.25 | 2023-2025 | Cuvitru, Takhzyro, Eohilia |
| Kaleo, INC. | $161.24 | 2021-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $159.18 | 2025 | Neffy |
| Grifols USA, LLC | $147.25 | 2024-2025 | Xembify, Gamunex-C |
| Hikma Pharmaceuticals USA | $97.48 | 2024-2025 | Ryaltris |
| Csl Behring | $95.79 | 2022-2025 | Hizentra, Andembry |
| Novartis Pharmaceuticals Corporation | $95.00 | 2024-2025 | |
| Pfizer INC. | $89.83 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $69.76 | 2024 | Orladeyo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.41 | 2024 | Tezspire, Actimmune |
| Azurity Pharmaceuticals, INC. | $47.30 | 2025 | Alvesco |
| Lilly USA, LLC | $38.20 | 2024-2025 | Ebglyss |
| Covis Pharma Gmbh | $33.21 | 2022 | |
| Ionis Pharmaceuticals, INC. | $17.11 | 2025 | Dawnzera |
| Leo Pharma INC. | $16.02 | 2024 | Adbry |
| Greer Laboratories, INC. | $15.54 | 2025 | Oralair |
| Abbvie INC. | $14.80 | 2024 | |
| Pharming Healthcare, INC. | $13.70 | 2024 | Ruconest |
| Organon LLC | $12.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.